Embecta Corp (EMBC)vsJohnson & Johnson (JNJ)
EMBC
Embecta Corp
$3.90
-57.84%
HEALTHCARE · Cap: $547.78M
JNJ
Johnson & Johnson
$224.62
-0.41%
HEALTHCARE · Cap: $546.90B
Smart Verdict
WallStSmart Research — data-driven comparison
Johnson & Johnson generates 8825% more annual revenue ($96.36B vs $1.08B). JNJ leads profitability with a 21.8% profit margin vs 12.9%. EMBC trades at a lower P/E of 3.9x. JNJ earns a higher WallStSmart Score of 59/100 (C).
EMBC
Buy56
out of 100
Grade: C
JNJ
Buy59
out of 100
Grade: C
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+78.6%
Fair Value
$46.96
Current Price
$3.90
$43.06 discount
Margin of Safety
-40.3%
Fair Value
$160.72
Current Price
$224.62
$63.90 premium
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Attractively priced relative to earnings
Earnings expanding 82.7% YoY
Conservative balance sheet, low leverage
Strong operational efficiency at 29.2%
Mega-cap, among the largest globally
Every $100 of equity generates 26 in profit
Keeps 22 of every $100 in revenue as profit
Strong operational efficiency at 27.4%
Generating 1.5B in free cash flow
Areas to Watch
Distress zone — elevated risk
Smaller company, higher risk/reward
ROE of 0.0% — below average capital efficiency
Revenue declined 0.3%
Moderate valuation
Expensive relative to growth rate
Earnings declined 52.9%
Comparative Analysis Report
WallStSmart ResearchBull Case : EMBC
The strongest argument for EMBC centers on P/E Ratio, EPS Growth, Debt/Equity.
Bull Case : JNJ
The strongest argument for JNJ centers on Market Cap, Return on Equity, Profit Margin. Profitability is solid with margins at 21.8% and operating margin at 27.4%.
Bear Case : EMBC
The primary concerns for EMBC are Altman Z-Score, Market Cap, Return on Equity.
Bear Case : JNJ
The primary concerns for JNJ are P/E Ratio, PEG Ratio, EPS Growth.
Key Dynamics to Monitor
EMBC profiles as a declining stock while JNJ is a mature play — different risk/reward profiles.
EMBC carries more volatility with a beta of 1.05 — expect wider price swings.
JNJ is growing revenue faster at 9.9% — sustainability is the question.
JNJ generates stronger free cash flow (1.5B), providing more financial flexibility.
Bottom Line
JNJ scores higher overall (59/100 vs 56/100), backed by strong 21.8% margins. EMBC offers better value entry with a 78.6% margin of safety. Both earn "Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Embecta Corp
HEALTHCARE · MEDICAL INSTRUMENTS & SUPPLIES · USA
Embecta Corp (EMBC) is a premier medical technology company specializing in innovative insulin delivery solutions for diabetes management. As a strategic spin-off from Becton, Dickinson and Company, Embecta utilizes state-of-the-art technologies and a diverse product portfolio, including insulin pens and syringes, to optimize patient care and improve health outcomes. With a strong commitment to operational excellence and a customer-centric approach, Embecta is well-positioned to seize growth opportunities in the rapidly evolving diabetes care market, aiming to enhance patient experiences while solidifying its leadership within the industry.
Visit Website →Johnson & Johnson
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Johnson & Johnson (J&J) is an American multinational corporation founded in 1886 that develops medical devices, pharmaceuticals, and consumer packaged goods. Its common stock is a component of the Dow Jones Industrial Average and the company is ranked No. 36 on the 2021 Fortune 500 list of the largest United States corporations by total revenue. Johnson & Johnson is one of the world's most valuable companies, and is one of only two U.S.-based companies that has a prime credit rating of AAA, higher than that of the United States government.
Visit Website →Compare with Other MEDICAL INSTRUMENTS & SUPPLIES Stocks
Want to dig deeper into these stocks?